India Myasthenia Gravis Treatment Market Size & Outlook
Related Markets
India myasthenia gravis treatment market highlights
- The India myasthenia gravis treatment market generated a revenue of USD 18.3 million in 2024 and is expected to reach USD 332.6 million by 2045.
- The India market is expected to grow at a CAGR of 13.2% from 2025 to 2045.
- In terms of segment, complement inhibitors was the largest revenue generating drug class in 2024.
- Complement Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Myasthenia gravis treatment market data book summary
| Market revenue in 2024 | USD 18.3 million |
| Market revenue in 2045 | USD 332.6 million |
| Growth rate | 13.2% (CAGR from 2025 to 2045) |
| Largest segment | Complement inhibitors |
| Fastest growing segment | Complement Inhibitors |
| Historical data | 2022 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2045 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Complement Inhibitors, Cholinesterase Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, India accounted for 0.6% of the global myasthenia gravis treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2045.
- In Asia Pacific, China myasthenia gravis treatment market is projected to lead the regional market in terms of revenue in 2045.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 332.6 million by 2045.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia Gravis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Avadel Pharmaceuticals PLC | View profile | 154 | 10 Earlsfort Terrace, Dublin 2, Dublin, Ireland, D02 T380 | https://www.avadel.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
India myasthenia gravis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Complement inhibitors was the largest segment with a revenue share of 85.25% in 2024. Horizon Databook has segmented the India myasthenia gravis treatment market based on complement inhibitors, cholinesterase inhibitors covering the revenue growth of each sub-segment from 2022 to 2045.
Presence of a large target population and increasing public-private initiatives to improve access to better treatment therapies are anticipated be major factors supporting market growth in the country. In addition, rising geriatric population and increasing risk of MG in this population group are anticipated to support market growth in the country.
According to a study published by Indian Journal of Ophthalmology, in India, MG is more prevalent in men than in women; the age of onset in men is in the sixth to seventh decade, and that in women is in the third decade.
According to a study published by NCBI, in January 2021, during COVID 19 pandemic, patients suffering from MG were associated with impaired activity of daily living, poor quality of life, & poor sleep quality.
Reasons to subscribe to India myasthenia gravis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India myasthenia gravis treatment market databook
-
Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into India myasthenia gravis treatment market from 2022 to 2045, including revenue numbers, major trends, and company profiles.
Partial client list
India myasthenia gravis treatment market size, by drug class, 2022-2045 (US$M)
India Myasthenia Gravis Treatment Market Outlook Share, 2024 & 2045 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
